The front page of AI-driven biology
Thursday, October 15, 2026Thu, Oct 15
Updated 6:32 PM PT
The confirmatory Phase 3 trial evaluated Lunsumio (mosunetuzumab), a bispecific antibody that redirects T cells to kill cancerous B cells by targeting CD20 and CD3, in earlier-line patients with follicular lymphoma.
Roche will pay Dualitas Therapeutics $36.5 million upfront to test more than 300,000 bispecific antibody pairings across immunology and inflammation targets.
The US Advanced Research Projects Agency for Health has unveiled the SPECTRA program, an effort combining computational tools and biological data to personalize autism care.
Novo Nordisk has agreed to a collaboration worth up to $1.4 billion with Orbis Medicines to develop oral macrocyclic peptides for cardiometabolic diseases.
Electra completed a $350 million initial public offering on Nasdaq to fund clinical development of its antibody pipeline, joining a wave of eleven biotech listings this year that have each raised at least $300 million.
High glucose levels induce direct tissue-level inflammation and epithelial cell detachment in human stem cell-derived kidney organoids, according to a study led by researchers at the University of Washington and the University of Miami.
The FDA approved Fayuvi, an adeno-associated virus gene therapy given into a vein to treat children with mucopolysaccharidosis type IIIA, also known as Sanfilippo syndrome type A. The one-time therapy uses an AAV9 viral vector to deliver a functional copy of the SGSH gene, allowing patients to produce sulfamidase and break down toxic accumulations of heparan sulfate in the brain.
Goa Therapeutics launched with $15.5 million in funding from individual industry leaders and filed for an initial public offering to raise up to $75 million.
The FDA granted priority review approval to Bayer's Kerendia, an oral non-steroidal mineralocorticoid receptor antagonist, to slow disease progression in adults with chronic kidney disease linked to Type 1 diabetes.
A Stanford team published an architecture in Science that coordinates specialized computational agents under a virtual chief scientific officer to analyze cross-disciplinary genomic, molecular, and clinical data.
A multiomics study published in Cell Reports Medicine by researchers at the Icahn School of Medicine at Mount Sinai mapped distinct tumor biology across developmental stages and sex in high-grade brain cancer.
An analysis of 23andMe genetic data across 3.37 million people published in Science found that the rare inherited T790M mutation in the EGFR gene increases lung cancer risk 62-fold in non-smokers.
Cardiometabolic biotech Marea Therapeutics will acquire Nasdaq-listed Lisata Therapeutics in an all-stock reverse merger alongside a $225 million private placement from RA Capital Management, Forbion, Third Rock Ventures, and Sofinnova Investments.
North Immunology will list on Nasdaq under ticker NRTX by merging with Aethlon Medical alongside a $180 million private placement backed by Bain Capital Life Sciences, Janus Henderson Investors, and Deep Track Capital.
OrbiMed and Qiming Venture Partners USA co-led the $25 million round, joined by Innovation Endeavors, Benchstrength, Fusion Fund, and Lumira Ventures.
SK Biopharmaceuticals will pay 1ST Biotherapeutics $1.8 million upfront, with total milestone potential bringing the headline deal value to $314.8 million, or roughly $315 million, for 1ST-104, an oral dual inhibitor of LRRK2 and c-Abl.
Longeveron is reviewing strategic options after its investigational cell therapy laromestrocel failed to beat control surgery in a Phase 2b trial of 40 infants with hypoplastic left heart syndrome.
Researchers built the Virtual Biotech, an ensemble of artificial intelligence agents organized into drug development divisions including target discovery, safety assessment, modality selection, and clinical trials.
Researchers applied a dynamic positive-unlabeled machine learning framework to evaluate mammal-virus associations worldwide, predicting tens of thousands of undocumented relationships.
Scientists developed MMAD-Risk, a multivariate survival model designed to predict long-term risk across 271 diseases simultaneously from blood plasma proteomic profiles.
Researchers combined machine-learning models of enzyme electrostatics with molecular mechanics and microkinetic modeling to simulate multistep catalytic reactions without relying on empirical approximations.
Bioengineers coupled the genomic foundation model gLM2 with discrete diffusion to guide the generative design of complex, multi-domain biosynthetic gene clusters.
The immgenT consortium developed immgenT-GP, a computational framework that deconvolves roughly 800,000 mouse T cells into 200 distinct, reproducible gene expression programs.
A benchmark evaluated three automated coding agents, Biomni, Claude Code, and Codex, on writing a complex Nextflow pipeline for processing epigenomic sequencing data from start to finish.
Computational biologists generated thermostable, de novo mini-proteins that bind Nipah and Hendra virus surface glycoproteins with subnanomolar affinity.
An update to the open-source ModelSEED Biochemistry Database expands the resource to approximately 46,000 compounds and 56,000 mass- and charge-balanced reactions for whole-cell metabolic modeling.
A computational protein-design system combined sparse experimental measurements with evolutionary and structural data to simultaneously engineer catalytic efficiency, expression yield, and thermal stability in the industrial ketoreductase Gre2.
Combining a metastatic colonization score called MetScore with standard classical-basal tumor subtypes better predicts patient survival and chemotherapy response in pancreatic ductal adenocarcinoma than the single-subtype model alone.
MicroClaw is an artificial intelligence assistant designed to plan and execute automated imaging experiments across multiple microscope platforms using natural language prompts.